loading
전일 마감가:
$0.94
열려 있는:
$0.9
하루 거래량:
593.80K
Relative Volume:
0.10
시가총액:
$7.22M
수익:
-
순이익/손실:
$-16.28M
주가수익비율:
-0.0697
EPS:
-13.91
순현금흐름:
$-13.75M
1주 성능:
+5.98%
1개월 성능:
-40.85%
6개월 성능:
-68.61%
1년 성능:
-83.42%
1일 변동 폭
Value
$0.90
$1.00
1주일 범위
Value
$0.788
$1.00
52주 변동 폭
Value
$0.788
$7.50

Pasithea Therapeutics Corp Stock (KTTA) Company Profile

Name
명칭
Pasithea Therapeutics Corp
Name
전화
(702) 514-4174
Name
주소
1111 LINCOLN ROAD, SUITE 500, MIAMI BEACH
Name
직원
4
Name
트위터
Name
다음 수익 날짜
2024-08-11
Name
최신 SEC 제출 서류
Name
KTTA's Discussions on Twitter

KTTA을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
KTTA
Pasithea Therapeutics Corp
0.97 6.81M 0 -16.28M -13.75M -13.91
Biotechnology icon
ONC
Beone Medicines Ltd Adr
245.58 26.10B 3.81B -644.79M -669.77M -6.24
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
442.05 111.96B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
AKTX
Akari Therapeutics Plc Adr
1.35 42.96M 0 0 0 0.00
Biotechnology icon
VRNA
Verona Pharma Plc Adr
81.20 6.39B 0 -153.72M -103.81M -2.00
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
490.28 63.52B 14.09B 4.50B 2.96B 39.28

Pasithea Therapeutics Corp 주식(KTTA)의 최신 뉴스

pulisher
May 20, 2025

Pasithea’s PAS-004 shows promise in inflammatory disease study - Investing.com Australia

May 20, 2025
pulisher
May 20, 2025

Pasithea Therapeutics Announces Preclinical Data That Shows PAS-004 Inhibits ETS2 Signaling, a Key Driver of Inflammation in IBD and Other Large Addressable Market Diseases - marketscreener.com

May 20, 2025
pulisher
May 20, 2025

Pasithea Therapeutics Reports Promising Preclinical Data for PAS-004 as a Novel MEK Inhibitor for Inflammatory Diseases - Nasdaq

May 20, 2025
pulisher
May 20, 2025

Pasithea Therapeutics Announces Preclinical Data that Shows - GlobeNewswire

May 20, 2025
pulisher
May 20, 2025

Breakthrough: Novel IBD Drug Outperforms FDA-Approved Treatment in Targeting Key Inflammation Pathway - Stock Titan

May 20, 2025
pulisher
May 15, 2025

Neurofibromatosis Type 1 Market Set to Witness Significant Growth During the Study Period (2020–2034) Driven by Advances in Treatment | DelveInsight - GlobeNewswire Inc.

May 15, 2025
pulisher
May 15, 2025

Pasithea to commence Phase I/Ib trial of neurofibromatosis type 1 therapy - Yahoo Finance

May 15, 2025
pulisher
May 14, 2025

Pasithea Therapeutics CEO sells shares worth $792 - Investing.com

May 14, 2025
pulisher
May 14, 2025

Pasithea Therapeutics Announces Initiation Of Phase 1/1B Study Of Pas-004 In Adult Nf1 Patients And Activation Of First Clinical Trial Site - marketscreener.com

May 14, 2025
pulisher
May 14, 2025

Pasithea Therapeutics Announces Initiation of Phase 1/1B - GlobeNewswire

May 14, 2025
pulisher
May 14, 2025

Phase 1/1b Trial: Pasithea's Once-Daily NF1 Drug Could Outperform Current Treatments - Stock Titan

May 14, 2025
pulisher
May 07, 2025

Pasithea Therapeutics Raises $6.3 Million in Stock Offering - TipRanks

May 07, 2025
pulisher
May 07, 2025

Pasithea Therapeutics Closes $5 Million Public Offering to Advance Development of PAS-004 for Neurofibromatosis and Cancer Indications - Nasdaq

May 07, 2025
pulisher
May 07, 2025

Pasithea Therapeutics Announces Closing of $5 Million Public Offering - GlobeNewswire

May 07, 2025
pulisher
May 07, 2025

Pasithea Therapeutics 3.57M share Secondary priced at $1.40 - Yahoo Finance

May 07, 2025
pulisher
May 06, 2025

Pasithea Therapeutics Stock Soars After Positive Data From Cancer Drug Trial: Retail’s Elated - Asianet Newsable

May 06, 2025
pulisher
May 06, 2025

Pasithea Therapeutics Announces Pricing Of $5 Million Public Offering - marketscreener.com

May 06, 2025
pulisher
May 06, 2025

Pasithea Therapeutics Stock Soars After Positive Data From Cancer Drug Trial: Retail’s Elated By Stocktwits - Investing.com India

May 06, 2025
pulisher
May 06, 2025

Pasithea Therapeutics Prices $5 Million Public Offering - marketscreener.com

May 06, 2025
pulisher
May 06, 2025

Pasithea Therapeutics announces interim data from Phase 1 trial of PAS-004 - TipRanks

May 06, 2025
pulisher
May 06, 2025

Pasithea Therapeutics Announces Pricing of $5 Million Public Offering - The Manila Times

May 06, 2025
pulisher
May 06, 2025

Pasithea Therapeutics (KTTA) Skyrockets: Stock Soars Over 115% in Morning Trade - apnakal

May 06, 2025
pulisher
May 06, 2025

$5M Public Offering: Pasithea Therapeutics Advances MEK Inhibitor Drug for Rare Disease Treatment - Stock Titan

May 06, 2025
pulisher
May 06, 2025

Pasithea Therapeutics Drug Shows Tumor Reduction In Pancreatic Cancer, Strong Early Trial Results - Benzinga

May 06, 2025
pulisher
May 06, 2025

Pre-market Movers: KTTA, SXTC, GLMD, TCMD... - RTTNews

May 06, 2025
pulisher
May 06, 2025

Pasithea reports promising data on cancer drug PAS-004 - Investing.com

May 06, 2025
pulisher
May 06, 2025

Pasithea reports promising data on cancer drug PAS-004 By Investing.com - Investing.com South Africa

May 06, 2025
pulisher
May 06, 2025

Pasithea Therapeutics Reports Promising Phase 1 Trial Results for PAS-004, Demonstrating Up to 91% pERK Inhibition and Tumor Volume Reduction in Advanced Cancer Patients - Nasdaq

May 06, 2025
pulisher
May 06, 2025

Pasithea Therapeutics Reports Positive Pharmacodynamic Results Demonstrating Robust Target Engagement from its Ongoing Phase 1 Clinical Trial of PAS-004 - GlobeNewswire

May 06, 2025
pulisher
May 06, 2025

Phase 1 Trial Reveals 91% Target Success: New Cancer Drug Shows Promise in Pancreatic Cancer Patient - Stock Titan

May 06, 2025
pulisher
May 01, 2025

Pasithea Therapeutics Files For Offering Up To 3.2 Mln Common Shares Together With Warrants, Says SEC Filing - marketscreener.com

May 01, 2025
pulisher
May 01, 2025

AMD Stock Signals Strong Buy Ahead of Earnings - The Globe and Mail

May 01, 2025
pulisher
Apr 29, 2025

Pasithea completes enrollment in cohort 6 of Phase 1 trial of PAS-004 - TipRanks

Apr 29, 2025
pulisher
Apr 29, 2025

Pasithea Therapeutics Announces Completion of Enrollment and Initial Dosing of Patients in Cohort 6 from its Phase 1 Trial of PAS-004 in Advanced Cancer Patients - The Manila Times

Apr 29, 2025
pulisher
Apr 29, 2025

Pasithea's Cancer Drug Trial Hits Key Milestone: Latest Results from Advanced Treatment Study - Stock Titan

Apr 29, 2025
pulisher
Apr 24, 2025

Pasithea Therapeutics Announces Acceptance of Abstract for ASCO 2025 Presentation on PAS-004 Clinical Trial Data - Nasdaq

Apr 24, 2025
pulisher
Apr 24, 2025

Pasithea Therapeutics to Present Updated Data from Ongoing - GlobeNewswire

Apr 24, 2025
pulisher
Apr 24, 2025

New PAS-004 Cancer Trial Data Shows Clinical Activity and Safety Profile | KTTA Stock News - Stock Titan

Apr 24, 2025
pulisher
Apr 15, 2025

Pasithea Therapeutics (NASDAQ:KTTA) Shares Down 16.9% – Here’s What Happened - Defense World

Apr 15, 2025
pulisher
Apr 14, 2025

Pasithea Therapeutics Leads Healthcare Buzz Surge As Cancer Trial Clears Safety Hurdle, Moves To Next Dosing C - Asianet Newsable

Apr 14, 2025
pulisher
Apr 11, 2025

12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga

Apr 11, 2025
pulisher
Apr 11, 2025

Pasithea Therapeutics Leads Healthcare Buzz Surge As Cancer Trial Clears Safety Hurdle, Moves To Next Dosing Cohort - MSN

Apr 11, 2025
pulisher
Apr 10, 2025

12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga

Apr 10, 2025
pulisher
Apr 10, 2025

Pasithea Therapeutics progresses with cancer drug trial By Investing.com - Investing.com South Africa

Apr 10, 2025
pulisher
Apr 10, 2025

Crude Oil Falls Over 4%; Keros Therapeutics Shares Jump - Benzinga

Apr 10, 2025
pulisher
Apr 10, 2025

Pasithea Therapeutics Gets Positive Safety Committee Recommendation for Advanced Cancer Drug Phase 1 Trial - marketscreener.com

Apr 10, 2025
pulisher
Apr 10, 2025

Dow Tumbles Over 800 Points; US Inflation Rate Falls In March - Benzinga

Apr 10, 2025
pulisher
Apr 10, 2025

KTTA’s Unexpected Surge: Analysis of Recent Performance - timothysykes.com

Apr 10, 2025
pulisher
Apr 10, 2025

12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga

Apr 10, 2025
pulisher
Apr 10, 2025

Pasithea Therapeutics progresses with cancer drug trial - Investing.com

Apr 10, 2025
pulisher
Apr 10, 2025

Pasithea Therapeutics Announces Positive Safety Review Committee (Src) Recommendation From Its Ongoing Phase 1 Clinical Trial Of Pas-004 In Advanced Cancer - MarketScreener

Apr 10, 2025

Pasithea Therapeutics Corp (KTTA) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading

Pasithea Therapeutics Corp 주식 (KTTA) 내부자 거래

내부자 거래 관계 날짜 거래 비용 #주식 가치 ($) #주식 총계
Marques Tiago
Chief Executive Officer
May 12 '25
Sale
0.82
960
792
40,001
$1.08
price up icon 1.89%
$30.14
price down icon 3.74%
$573.26
price down icon 1.32%
$304.56
price up icon 3.98%
$4.50
price down icon 3.02%
$490.28
price down icon 19.01%
자본화:     |  볼륨(24시간):